Therapeutic inhibition of RAS in non-small cell lung cancer - Top-Institutions - MDSpire

Therapeutic inhibition of RAS in non-small cell lung cancer

  • By

  • Katherine B. Nichols

  • Benjamin O. Herzberg

  • June 30, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Moffitt Cancer Center
    Moffitt Cancer Center

    Tampa, Florida

    Key Differentiators

    • Oncology

  • #2

    Yale Cancer Center
    Yale Cancer Center

    New Haven, Connecticut

    Key Differentiators

    • Oncology

  • #3

    University of California, Davis, Comprehensive Cancer Center
    University of California, Davis, Comprehensive Cancer Center

    Sacramento, California

    Key Differentiators

    • Oncology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #5

    Winship Cancer Institute of Emory University
    Winship Cancer Institute of Emory University

    Atlanta, Georgia

    Key Differentiators

    • Oncology

Original Source(s)

Therapeutic inhibition of RAS in non-small cell lung cancer

  • by Katherine B. Nichols, Benjamin O. Herzberg

  • June 30, 2026

Related Content

Mixed adenoneuroendocrine carcinoma of the gallbladder: a case report and literature review

Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology

Supreme Court ruling on Roundup points to a confusing difference between the law and science